Stockscreener 앱 받기
7.47
3.11%
-0.24
전일 마감가:
$7.71
열려 있는:
$7.79
하루 거래량:
1.28M
Relative Volume:
0.73
시가총액:
$1.04B
수익:
$62.04M
순이익/손실:
$-533.34M
주가수익비율:
-1.9056
EPS:
-3.92
순현금흐름:
$-473.07M
1주 성능:
+3.89%
1개월 성능:
+18.38%
6개월 성능:
+63.46%
1년 성능:
-22.03%
1일 변동 폭
$7.375
$7.89
1주일 범위
$7.01
$7.89
52주 변동 폭
$4.155
$10.01
비르 바이오테크 Stock (VIR) Company Profile
명칭
Vir Biotechnology Inc
전화
415-906-4324
주소
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
7.47 | 1.07B | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
비르 바이오테크 Stock (VIR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-03 | 개시 | Evercore ISI | Outperform |
| 2025-08-27 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-09-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-03-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-02-21 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 개시 | SVB Leerink | Outperform |
| 2022-09-09 | 개시 | Morgan Stanley | Underweight |
| 2022-03-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-09-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-01-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-09-14 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-11 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 개시 | Needham | Buy |
| 2020-03-19 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-03-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-02-27 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 개시 | Robert W. Baird | Neutral |
| 2019-11-05 | 개시 | Barclays | Overweight |
| 2019-11-05 | 개시 | Cowen | Outperform |
| 2019-11-05 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | JP Morgan | Overweight |
모두보기
비르 바이오테크 주식(VIR)의 최신 뉴스
Can Vir Biotechnology Inc. stock hit analyst price targetsJuly 2025 Rallies & Low Risk Growth Stock Ideas - mfd.ru
How cyclical is Vir Biotechnology Inc.’s revenue stream2025 Market Sentiment & Technical Pattern Based Signals - mfd.ru
Vir Biotechnology, Inc. (VIR) Stock Analysis: A 111.85% Potential Upside Amidst Challenging Metrics - DirectorsTalk Interviews
Is Vir Biotechnology Inc. subject to activist investor interestJuly 2025 Earnings & Weekly High Potential Stock Alerts - mfd.ru
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), M3 (OtherMTHRF) and Sarepta Therapeutics (SRPT) - The Globe and Mail
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results - PharmiWeb.com
Vir Biotechnology to unveil Q4 and full year 2025 earnings results - Traders Union
Press Release: Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results - 富途牛牛
Vir Biotechnology (NASDAQ:VIR) Earns Buy Rating from Needham & Company LLC - MarketBeat
Needham Reiterates Buy Rating for VIR with $14 Price Target | VI - GuruFocus
VIR News Today | Why did Vir Biotechnology stock go down today? $VIR - MarketBeat
Vir Biotechnology: The Low-Down On The Readouts Ahead - Seeking Alpha
Vir Biotechnology price target lowered to $24 from $31 at Barclays - TipRanks
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares - MarketBeat
Vir Biotechnology director Sato sells $169k in stock By Investing.com - Investing.com Canada
Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown - MSN
Vir Biotechnology, Inc. (VIR) Stock Analysis: A Biotech with a Promising 131% Upside Potential - DirectorsTalk Interviews
Vir Biotechnology (VIR) Is Up 19.4% After Strong Dual-Therapy Data in Hepatitis Delta Trial - Yahoo Finance
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Trading Recap: What makes Stran Company Inc Equity Warrant stock attractive today2025 Price Targets & Smart Investment Allocation Tips - baoquankhu1.vn
Aug Update: Can Vir Biotechnology Inc outperform under higher oil pricesJuly 2025 Earnings & Short-Term Swing Trade Alerts - baoquankhu1.vn
Vir Biotechnology (NASDAQ:VIR) Shares Up 9.9%Should You Buy? - MarketBeat
Aug Macro: Can BankUnited Inc outperform under higher oil prices2025 Risk Factors & Daily Market Momentum Tracking - baoquankhu1.vn
Aug Final Week: Is Vir Biotechnology Inc a strong growth stock2025 Investor Takeaways & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Raymond James Sticks to Their Buy Rating for Vir Biotechnology (VIR) - The Globe and Mail
Vir Biotechnology (NASDAQ:VIR) Top 10 Nasdaq Stocks Spotlight on Research - Kalkine Media
Vir Biotechnology (VIR) Advances in Hepatitis Delta Treatment - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Trading 7.3% HigherWhat's Next? - MarketBeat
Vir Biotechnology shows positive results in hepatitis delta trial - Traders Union
Vir Biotechnology (VIR) Reports Positive Trial Results in Hepati - GuruFocus
Vir Biotechnology reports promising results for hepatitis delta therapy By Investing.com - Investing.com Nigeria
Vir Biotechnology reports promising results for hepatitis delta therapy - Investing.com
Vir Biotechnology reports positive Phase 2 hepatitis delta data, outlines 2026 clinical milestones - MSN
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones - BioSpace
Vir Biotechnology advances hepatitis delta program and cash runway - TipRanks
Vir Biotechnology provides updates on chronic hepatitis Delta and oncology programs and upcoming 2026 clinical milestones - marketscreener.com
Vir Biotechnology reports positive hepatitis delta trial data - StreetInsider
Vir Biotechnology Provides Updates On Chronic Hepatitis Delta And Oncology Programs And Upcoming 2026 Clinical Milestones - TradingView — Track All Markets
How Vir Biotechnology Inc. stock performs after earnings2025 Biggest Moves & Verified Momentum Stock Watchlist - ulpravda.ru
Is Vir Biotechnology Inc. stock a safe haven assetWeekly Profit Analysis & Weekly Stock Breakout Alerts - Улправда
Will Vir Biotechnology Inc. stock keep outperforming rivalsJuly 2025 Big Picture & Low Risk Investment Opportunities - Улправда
Profit Recap: Can Vir Biotechnology Inc. stock beat market expectations this quarterEarnings Summary Report & Free High Accuracy Swing Entry Alerts - Улправда
Bank of America Securities Keeps Their Buy Rating on Vir Biotechnology (VIR) - The Globe and Mail
Vir Biotechnology issues license to Norgine to market hepatitis D candidate - MSN
Hepatitis B Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Arbutus Biopharma, GSK/Ionis Pharma, Vir Biotech, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp - The Globe and Mail
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference - 富途牛牛
Vicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Sell Signal: Will Vir Biotechnology Inc stock benefit from M A activityJuly 2025 Decliners & Expert Verified Movement Alerts - Bộ Nội Vụ
비르 바이오테크 (VIR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
비르 바이오테크 주식 (VIR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SATO VICKI L | Director |
Feb 02 '26 |
Sale |
7.71 |
22,000 |
169,671 |
1,144,391 |
1.12%
0.87%
자본화:
|
볼륨(24시간):